Details of the Drug

General Information of Drug (ID: DMODLN7)

Drug Name

IRX-2

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[1]
Head and neck cancer	2D42	Phase 2	[1]
Squamous cell carcinoma	2B60-2D01	Phase 2	[2]
Breast cancer	2C60-2C65	Phase 1	[3]
leukaemia	2A60-2B33	Investigative	[4]
------------------------------------------------------------------------------------

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytokine receptor unspecific (CRF)	TTXM6JN	NOUNIPROTAC	Modulator	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT00210470) A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5	Clinical pipeline report, company report or official report of IRX Therapeutics.